Rockefeller Capital Management L.P. Sells 100,313 Shares of DexCom, Inc. (NASDAQ:DXCM)

Rockefeller Capital Management L.P. reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 86.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,394 shares of the medical device company’s stock after selling 100,313 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in DexCom were worth $1,042,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in DXCM. QRG Capital Management Inc. lifted its holdings in DexCom by 32.6% in the 2nd quarter. QRG Capital Management Inc. now owns 14,449 shares of the medical device company’s stock worth $1,638,000 after buying an additional 3,553 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in DexCom by 6.4% in the second quarter. Sequoia Financial Advisors LLC now owns 7,376 shares of the medical device company’s stock valued at $836,000 after acquiring an additional 445 shares in the last quarter. Diversified Trust Co raised its holdings in DexCom by 1.8% in the 2nd quarter. Diversified Trust Co now owns 60,281 shares of the medical device company’s stock worth $6,835,000 after purchasing an additional 1,057 shares in the last quarter. NorthCrest Asset Manangement LLC lifted its position in shares of DexCom by 11.2% in the 2nd quarter. NorthCrest Asset Manangement LLC now owns 26,076 shares of the medical device company’s stock worth $2,956,000 after purchasing an additional 2,625 shares during the period. Finally, Financial Insights Inc. bought a new stake in shares of DexCom during the 2nd quarter valued at about $242,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company increased their price target on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Piper Sandler restated an “overweight” rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. JPMorgan Chase & Co. increased their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Leerink Partners decreased their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $104.59.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.30% of the company’s stock.

DexCom Stock Down 1.5 %

DXCM stock opened at $77.72 on Monday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The stock has a market capitalization of $30.36 billion, a P/E ratio of 46.54, a P/E/G ratio of 2.48 and a beta of 1.12. The business has a fifty day moving average price of $72.55 and a 200-day moving average price of $85.74.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.